Related Experiment Video
Updated: Jan 31, 2026

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
Targeting modulated vascular smooth muscle cells in atherosclerosis via FAP-directed immunotherapy
Junedh M Amrute1,2,3,4,5, In-Hyuk Jung1,5, Tracy Yamawaki2
1Center for Cardiovascular Research, Division of Cardiology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.
Abstract:
Vascular smooth muscle cell (VSMC) diversification drives atherosclerotic coronary artery disease (CAD). Mechanisms governing these cell state transitions remain unclear. We applied multiomic single-cell profiling, epitope mapping, and spatial transcriptomics across 27 human coronary arteries, identifying fibroblast activation protein (FAP) as a marker of modulated VSMCs. Lineage tracing in mice indicated that FAP+ cells originate from Myh11+ VSMCs, and FAP PET imaging in CAD patients showed plaque uptake. FAP+ cells states resided in the macrophage-rich neo-intima. Therapeutically, we developed an anti-FAP bispecific T-cell engager, which reduced plaque burden and remodeled the stromal-immune microenvironment through T-cell clonal expansion. Our study delivers a single-cell and spatial atlas of human CAD, establishes FAP as a marker of modulated VSMCs, and highlights immunotherapy for lipid-independent targets.
Insights
Fibroblast activation protein (FAP) marks changing vascular smooth muscle cells in coronary artery disease (CAD). Targeting FAP with immunotherapy offers a new treatment strategy for CAD.
Area of Science:
- Cardiovascular Biology
- Immunology
- Translational Medicine
Background:
- Vascular smooth muscle cell (VSMC) diversification is a key driver of atherosclerotic coronary artery disease (CAD).
- The precise mechanisms controlling VSMC state transitions in CAD remain largely unknown.
- Understanding these cellular dynamics is crucial for developing effective CAD therapies.
Purpose of the Study:
- To elucidate the cellular mechanisms underlying VSMC diversification in human CAD.
- To identify novel cellular markers and therapeutic targets for atherosclerotic disease.
- To evaluate the potential of targeting identified markers for CAD immunotherapy.
Main Methods:
- Multiomic single-cell profiling and spatial transcriptomics were performed on 27 human coronary arteries.
- Epitope mapping and lineage tracing in mouse models were utilized.
- Positron emission tomography (PET) imaging with FAP tracers was conducted in CAD patients.
- Development and testing of an anti-FAP bispecific T-cell engager therapy.
Main Results:
- Fibroblast activation protein (FAP) was identified as a marker for modulated VSMCs in human CAD.
- FAP-expressing cells were found to originate from Myh11+ VSMCs and reside in the macrophage-rich neo-intima.
- FAP PET imaging demonstrated significant plaque uptake in CAD patients.
- Therapeutic intervention with an anti-FAP bispecific T-cell engager reduced atherosclerotic plaque burden and modulated the stromal-immune microenvironment.
Conclusions:
- This study provides a comprehensive single-cell and spatial atlas of human CAD, revealing key cellular players.
- FAP is established as a reliable marker for VSMC modulation in the context of atherosclerosis.
- Targeting FAP via immunotherapy presents a promising lipid-independent therapeutic strategy for CAD.
Related Concept Videos
Functions of Smooth Muscles
Function of visceral smooth muscles
Visceral smooth muscle is found in the walls of all hollow organs, except the heart, and is a key player in the involuntary movements that drive the functioning of these internal organs. This tissue is arranged in...
Smooth Muscle Contraction
The onset of contraction is triggered by an increase in calcium ions within the sarcoplasm, similar to the process in striated muscle. However, smooth muscles have a relatively smaller reservoir of the sarcoplasmic...
Structure and Organization of Smooth Muscles
Structure of smooth muscle cell
Smooth muscle cells are spindle-shaped with tapering ends and a...
Tumor Immunotherapy
Atherosclerosis III: Management
Atherosclerosis I: Introduction

